The pharmaceutical sector surges! E Fund Bio-Pharmaceutical ETF (3186.HK) jumps over 6%

On April 1, the biopharmaceutical sector saw a strong surge, with related stocks across Hong Kong and A shares rising across the board. The E Fund Biopharmaceutical ETF (3186.HK) jumped more than 6% intraday, and all of its top ten constituent stocks gained.

The ETF closely tracks the Solactive Biopharmaceutical Select Index. It is currently the only biopharmaceutical index product globally that spans the two major pharmaceutical core markets of China and the U.S., providing investors with an efficient tool to quickly build exposure to global biopharmaceutical innovation. The index selects 100 high-quality biopharmaceutical constituent stocks listed in Hong Kong and the U.S., covering global innovation hubs such as China, the U.S., and Europe. It uses equal-weight construction, with stock allocation highly diversified, enabling balanced capture of innovation opportunities.

The market surge was driven by a convergence of multiple favorable factors: at the policy level, biopharmaceuticals have been listed as a national emerging pillar industry; in terms of performance, the industry has entered a period of earnings delivery, and several leading companies have turned losses into profits; regarding event catalysts, the AACR annual meeting is just around the corner, and achievements from Chinese pharmaceutical companies are highly anticipated.

（责任编辑: Dong Pingping ）

     【Disclaimer】This article only represents the author’s personal views and is not related to Hexun. Hexun’s website maintains a neutral stance toward the statements and views expressed in the text, and does not provide any express or implied guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use this information only as reference and bear all responsibility themselves. Email: news_center@staff.hexun.com